FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus

Figure 1 Baseline area-under-the-receiver-operating-curve analysis for stages F2-4 for FibroSURE and transient elastography. Of the overall cohort with baseline biopsy (n = 2060), FibroSURE (FS) was available in 2055 patients, transient elastography (TE) in 214, and both FS and TE in 209. Area-under-the-receiver-operating-curve values for stages F2-4 were 0.82 for FS, 0.88 for TE, and 0.88 for FS + TE. Differences between FS and TE were not significant. FS: FibroSURE; TE: Transient elastography.

Figure 2 Boxplot distribution of FibroSURE index scores in all patients at baseline (n = 2055). Box parameters represent 25th and 75th percentile index scores for each fibrosis stage; median index values are shown within box, and upper and lower range limits are represented by vertical lines.

Figure 3 Changes in transient elastography with therapy according to sustained virological response. Mean FibroScan fibrosis scores over time by sustained virological response status in patients with hepatitis C virus (A) genotypes 2/3 and (B) genotype 1. FU: Follow-up.

Figure 4 Changes in FibroSURE with therapy according to sustained virological response. Changes in FibroSURE (A) fibrosis index and (B) inflammatory index at 12 wk post-treatment compared with baseline values by sustained virological response status.